Related Experiment Videos
Plasma transforming growth factor beta1 in breast cancer patients treated with CMF chemotherapy
D Kajdaniuk1, B Marek, E Swietochowska
1Department of Pathophysiology & Endocrinology, Silesian Medical University, Zabrze, Poland.
Background:
In early breast cancer patients the transformed epithelial cells are thought to be sensitive to transforming growth factor beta1 (TGFbeta1)-mediated growth arrest. TGFbeta1 may therefore act as an anti-tumour promoter. However, in advanced breast cancer resistance to such TGFbeta1 action develops. Neoplastic cells produce TGFbeta1, which may enhance tumour invasion and metastasis, mainly by intensifying angiogenesis, which is an immunosuppressive action. In the light of the potential role of TGFbeta1 in breast cancer pathogenesis, an understanding of the effect of applied therapeutic methods on plasma TGFbeta1 concentration is essential.
Objective:
To investigate the effect of adjuvant chemotherapy on plasma transforming growth factor beta1 (TGFbeta1) concentration in breast cancer patients with metastases to axillary lymph nodes.
Method:
Fifteen stage II breast cancer patients on adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) were studied along with 15 healthy premenopausal women.
Results:
Plasma TGFbeta1 concentration (determined by the ELISA method) in the breast cancer patients did not differ significantly from that of the healthy women. Adjuvant CMF chemotherapy significantly decreased plasma TGFbeta1 concentration in those pre-menopausal breast cancer women with metastases to axillary lymph nodes.
Conclusion:
The possible pathogenic action of this growth factor in stage II breast cancer disease warrants further investigation to elucidate whether the induced decrease of blood TGFbeta1 concentration is essential to successful chemotherapy.
Insights
Adjuvant chemotherapy, specifically CMF, significantly reduced plasma transforming growth factor beta1 (TGFbeta1) levels in pre-menopausal breast cancer patients with lymph node metastases. This finding suggests a potential role for TGFbeta1 modulation in successful breast cancer treatment.
Area of Science:
- Oncology
- Immunology
- Biochemistry
Background:
- Transforming growth factor beta1 (TGFbeta1) is implicated in breast cancer progression, potentially promoting invasion and metastasis.
- While TGFbeta1 can induce growth arrest in early breast cancer, resistance develops in advanced stages.
- Understanding TGFbeta1's role in pathogenesis necessitates studying its plasma levels in response to therapy.
Purpose of the Study:
- To evaluate the impact of adjuvant chemotherapy on plasma TGFbeta1 concentrations.
- To investigate this effect specifically in breast cancer patients with axillary lymph node metastases.
Main Methods:
- Study included 15 stage II breast cancer patients receiving adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy.
- A control group of 15 healthy premenopausal women was included for comparison.
- Plasma TGFbeta1 levels were quantified using the Enzyme-Linked Immunosorbent Assay (ELISA) method.
Main Results:
- Initial plasma TGFbeta1 concentrations did not significantly differ between breast cancer patients and healthy controls.
- Adjuvant CMF chemotherapy led to a significant decrease in plasma TGFbeta1 levels.
- This reduction was observed specifically in pre-menopausal breast cancer patients with lymph node metastases.
Conclusions:
- The study demonstrates that CMF chemotherapy can decrease plasma TGFbeta1 concentrations in a specific subset of breast cancer patients.
- Further research is warranted to explore the pathogenic role of TGFbeta1 in stage II breast cancer.
- Investigating whether this chemotherapy-induced reduction in TGFbeta1 is crucial for treatment success is essential.